130 related articles for article (PubMed ID: 23452008)
1. Axitinib for the treatment of advanced non-small-cell lung cancer.
King JW; Lee SM
Expert Opin Investig Drugs; 2013 Jun; 22(6):765-73. PubMed ID: 23452008
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic evaluation of axitinib.
Patson B; B Cohen R; Olszanski AJ
Expert Opin Drug Metab Toxicol; 2012 Feb; 8(2):259-70. PubMed ID: 22248343
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
[TBL] [Abstract][Full Text] [Related]
4. BIBF 1120/ nintedanib : a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer.
Rolfo C; Raez LE; Bronte G; Santos ES; Papadimitriou K; Buffoni L; van Meerbeeck JP; Russo A
Expert Opin Investig Drugs; 2013 Aug; 22(8):1081-8. PubMed ID: 23790097
[TBL] [Abstract][Full Text] [Related]
5. Axitinib for the treatment of advanced renal cell carcinoma.
Akaza H; Fukuyama T
Expert Opin Pharmacother; 2014 Feb; 15(2):283-97. PubMed ID: 24328549
[TBL] [Abstract][Full Text] [Related]
6. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
Raben D; Helfrich B; Bunn PA
Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
[TBL] [Abstract][Full Text] [Related]
8. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
Patel JD; Pasche B; Argiris A
Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824
[TBL] [Abstract][Full Text] [Related]
9. BIBF 1120 for the treatment of non-small cell lung cancer.
Reck M
Expert Opin Investig Drugs; 2010 Jun; 19(6):789-94. PubMed ID: 20465363
[TBL] [Abstract][Full Text] [Related]
10. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
Manegold C
Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
[TBL] [Abstract][Full Text] [Related]
11. Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer.
Skouras VS; Maragkos C; Grapsa D; Syrigos KN
BioDrugs; 2016 Oct; 30(5):421-439. PubMed ID: 27670779
[TBL] [Abstract][Full Text] [Related]
12. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions.
Ellis PM; Al-Saleh K
Crit Rev Oncol Hematol; 2012 Oct; 84(1):47-58. PubMed ID: 22405734
[TBL] [Abstract][Full Text] [Related]
13. Targeting VEGF in lung cancer.
Das M; Wakelee H
Expert Opin Ther Targets; 2012 Apr; 16(4):395-406. PubMed ID: 22439677
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
[TBL] [Abstract][Full Text] [Related]
15. Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer.
Socinski MA
Cancer Treat Rev; 2011 Dec; 37(8):611-7. PubMed ID: 21641723
[TBL] [Abstract][Full Text] [Related]
16. The potential of antiangiogenic therapy in non-small cell lung cancer.
Giaccone G
Clin Cancer Res; 2007 Apr; 13(7):1961-70. PubMed ID: 17404076
[TBL] [Abstract][Full Text] [Related]
17. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
Bunn PA; Thatcher N
Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
[TBL] [Abstract][Full Text] [Related]
18. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib for non-small-cell lung cancer treatment.
D'Incecco A; Cappuzzo F
Expert Opin Drug Saf; 2011 Nov; 10(6):987-96. PubMed ID: 21905963
[TBL] [Abstract][Full Text] [Related]
20. Motesanib and advanced NSCLC: experiences and expectations.
Raghav KP; Blumenschein GR
Expert Opin Investig Drugs; 2011 Jun; 20(6):859-69. PubMed ID: 21534718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
